The role of SPMs in metabolic health

Metabolic disorders exhibit strong inflammatory underpinnings and in turn, inflammation is associated with metabolic changes. Obesity is significantly linked to increased risk of metabolic disease. Overeating, observed in obesity, increases the immune response, causing the body to generate excessive, low-grade inflammation – known as metabolic-triggered inflammation – which may lead to a number of chronic diseases, like diabetes, hypertension and non-alcoholic fatty liver disease.

SPM levels appear to be lower in individuals with obesity, which may be the reason for unresolved inflammation in the condition. Although the pathways are still being explored, one of the mechanisms resulting in decreased SPM levels in obesity is a change in the enzyme activities involved in the biosynthesis or conversion of SPMs from their precursors EPA and DHA omega 3s. Therefore, supplementation may help to enhance resolution and improve insulin sensitivity, offering a more targeted approach than simply increasing omega-3 fatty acids in the diet.